{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:09:32Z","timestamp":1792523372202,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe aplastic anemia (SAA) is a rare, life-threatening disease with acquired pancytopenia and hypocellular bone marrow. ESCALATE evaluated eltrombopag in combination with immunosuppressive therapy (IST) in pediatric patients (aged 1 to &amp;lt;18 years) with relapsed\/refractory (R\/R) or treatment-na\u00efve SAA. The eltrombopag starting dose was 25 mg\/d for patients aged 1 to &amp;lt;6 years and 50 mg\/d for patients aged 6 to &amp;lt;18 years; dose modifications (maximum dose, 150 mg\/d) were allowed to achieve a target platelet count of 50 \u00d7 109\/L to 200 \u00d7 109\/L. Eltrombopag was administered with cyclosporine A, with or without horse antithymocyte globulin, for 26 weeks and could be extended if clinically beneficial. Fifty-one patients were treated (R\/R SAA, n = 14; treatment-na\u00efve SAA, n = 37). Data were analyzed overall and as 2 cohorts: R\/R and treatment-na\u00efve cohorts. The overall response rate (ORR; per North American Pediatric Aplastic Anemia Consortium criteria) at 26 weeks was 54.9% in both cohorts combined and 71.4% and 48.6% in the R\/R and treatment-na\u00efve cohorts, respectively; most responders had sustained responses after discontinuing eltrombopag. Among baseline transfusion-dependent patients, 66.7% and 76.7% achieved red blood cell and platelet transfusion independence, respectively, with rates of 70% and 80% for the R\/R cohort and 65.6% and 75.8% for the treatment-na\u00efve cohort, respectively. The most common treatment-related adverse events were abnormalities in liver function tests, including increased bilirubin (43.1%), alanine aminotransferase (37.3%), and aspartate aminotransferase (33.3%). Eltrombopag with IST showed a trend toward a favorable ORR in the R\/R cohort, with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT03025698.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015102","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T15:12:14Z","timestamp":1746198734000},"page":"3728-3738","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4683-9958","authenticated-orcid":false,"given":"Akiko","family":"Shimamura","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-6698","authenticated-orcid":false,"given":"Alexey","family":"Maschan","sequence":"additional","affiliation":[{"name":"2Department of General Hematology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Bennett","sequence":"additional","affiliation":[{"name":"3Hematology\/Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Samarasinghe","sequence":"additional","affiliation":[{"name":"4Department of Paediatric Haematology, Great Ormond Street Hospital for Children, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-5839","authenticated-orcid":false,"given":"Jason E.","family":"Farrar","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Arkansas Children's Research Institute and University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-5758","authenticated-orcid":false,"given":"Chi-kong","family":"Li","sequence":"additional","affiliation":[{"name":"6Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nongnuch","family":"Sirachainan","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-0118","authenticated-orcid":false,"given":"Bunchoo","family":"Pongtanakul","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6804-9121","authenticated-orcid":false,"given":"Patcharee","family":"Komvilaisak","sequence":"additional","affiliation":[{"name":"9Department of Pediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"Zubarovskaya","sequence":"additional","affiliation":[{"name":"10RM Gorbacheva Research Institute, Pavlov First State Medical University of St. Petersburg, St Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-2886","authenticated-orcid":false,"given":"Jennifer A.","family":"Rothman","sequence":"additional","affiliation":[{"name":"11Division of Pediatric Hematology and Oncology, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Walkovich","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Oncology, University of Michigan, C. S. Mott Children's Hospital, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo A.","family":"Nakano","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics, Center for Cancer and Blood Disorders, Children\u2019s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1864-8502","authenticated-orcid":false,"given":"Alison A.","family":"Bertuch","sequence":"additional","affiliation":[{"name":"14Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-1679","authenticated-orcid":false,"given":"Anabela","family":"Ferrao","sequence":"additional","affiliation":[{"name":"15Department of Pediatrics Centro Hospitalar Universit\u00e1rio Lisboa Norte, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhmi","family":"Bhat","sequence":"additional","affiliation":[{"name":"16Division of Hematology\/Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[{"name":"17Department of Pediatric Hematology, Oncology and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Overholt","sequence":"additional","affiliation":[{"name":"18Division of Hematology, Oncology, and Stem Cell Transplant, Riley Children\u2019s Health at Indiana University, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Boklan","sequence":"additional","affiliation":[{"name":"19Department of Pediatrics, University of Arizona College of Medicine, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-3926","authenticated-orcid":false,"given":"Tze Fang","family":"Wong","sequence":"additional","affiliation":[{"name":"20OGD\/OCD Oncology, Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxia","family":"Wang","sequence":"additional","affiliation":[{"name":"21GPT Statistics, Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Urban","sequence":"additional","affiliation":[{"name":"20OGD\/OCD Oncology, Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-130X","authenticated-orcid":false,"given":"Brigitte","family":"Strahm","sequence":"additional","affiliation":[{"name":"22Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfred","family":"Wang","sequence":"additional","affiliation":[{"name":"23Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4068-5406","authenticated-orcid":false,"given":"Adrianna","family":"Vlachos","sequence":"additional","affiliation":[{"name":"24Division of Hematology\/Oncology and Stem Cell Transplantation, Cohen Children's Medical Center, New Hyde Park, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Dana-Farber\/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"2025081209213887400_bib1","doi-asserted-by":"crossref","first-page":"1378432","DOI":"10.3389\/fimmu.2024.1378432","article-title":"The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults","volume":"15","author":"Piekarska","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"2025081209213887400_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/ejh.13153","article-title":"Aplastic anemia: etiology, molecular pathogenesis, and emerging concepts","volume":"101","author":"Shallis","year":"2018","journal-title":"Eur J Haematol"},{"issue":"8","key":"2025081209213887400_bib3","doi-asserted-by":"crossref","first-page":"e31075","DOI":"10.1002\/pbc.31075","article-title":"Treatment of relapsed\/refractory severe aplastic anemia in children: evidence-based recommendations","volume":"71","author":"Shimano","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2025081209213887400_bib4","doi-asserted-by":"crossref","first-page":"e31070","DOI":"10.1002\/pbc.31070","article-title":"Treatment of newly diagnosed severe aplastic anemia in children: evidence-based recommendations","volume":"71","author":"Shimano","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2025081209213887400_bib5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jpeds.2008.06.004","article-title":"Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine","volume":"153","author":"Scheinberg","year":"2008","journal-title":"J Pediatr"},{"issue":"10","key":"2025081209213887400_bib6","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3324\/haematol.2018.206540","article-title":"Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study","volume":"104","author":"Rogers","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"2025081209213887400_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3324\/haematol.2014.109355","article-title":"First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy","volume":"99","author":"Yoshida","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"2025081209213887400_bib8","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3324\/haematol.2014.106096","article-title":"Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"99","author":"Dufour","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2025081209213887400_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jped.2014.02.004","article-title":"Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A","volume":"90","author":"Garanito","year":"2014","journal-title":"J Pediatr"},{"issue":"3","key":"2025081209213887400_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.17233","article-title":"Paediatric severe aplastic anaemia treatment: where to start?","volume":"192","author":"Olson","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"2025081209213887400_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"2025081209213887400_bib12","unstructured":"A trial comparing unrelated donor BMT with IST for pediatric and young adult patients with severe aplastic anemia (TransIT, BMT CTN 2202) (TransIT). ClinicalTrials.gov identifier: NCT05600426. Updated 7 May 2025. Accessed 30 January 2025. https:\/\/clinicaltrials.gov\/study\/NCT05600426?term=NCT05600426&rank=1."},{"issue":"10","key":"2025081209213887400_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17474086.2019.1645003","article-title":"Management of aplastic anemia after failure of frontline immunosuppression","volume":"12","author":"Pierri","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"2025081209213887400_bib14","unstructured":"Promacta\n          . Highlights of prescribing information. Novartis; 2023. Accessed 18 June 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/promacta.pdf."},{"issue":"16","key":"2025081209213887400_bib15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2025081209213887400_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"2025081209213887400_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V45.3.355.355","article-title":"Selection of patients for bone marrow transplantation in severe aplastic anemia","volume":"45","author":"Camitta","year":"1975","journal-title":"Blood"},{"key":"2025081209213887400_bib18","author":"Swerdlow","year":"2017","edition":"Revised 4th ed"},{"issue":"8","key":"2025081209213887400_bib19","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"7","key":"2025081209213887400_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/08880018.2021.1895924","article-title":"Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study","volume":"38","author":"Fang","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"7","key":"2025081209213887400_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/08880018.2021.1900475","article-title":"Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children","volume":"38","author":"Jie","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"8","key":"2025081209213887400_bib22","doi-asserted-by":"crossref","first-page":"e29066","DOI":"10.1002\/pbc.29066","article-title":"Eltrombopag in children with severe aplastic anemia","volume":"68","author":"Lesmana","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2025081209213887400_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjh.17232","article-title":"Eltrombopag added to immunosuppression for children with treatment-na\u00efve severe aplastic anaemia [published correction appears in Br J Haematol. 2022;197(5):640-641]","volume":"192","author":"Groarke","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"2025081209213887400_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/bloodadvances.2021006716","article-title":"Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia","volume":"7","author":"Goronkova","year":"2023","journal-title":"Blood Adv"},{"key":"2025081209213887400_bib25","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-024-03253-w","article-title":"Eltrombopag combined with immunosuppressive therapy for pediatric severe aplastic anemia","author":"Yang","year":"31  2024","journal-title":"Pediatr Res"},{"issue":"1","key":"2025081209213887400_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia [published correction appears in N Engl J Med. 2012;367(3):284]","volume":"367","author":"Olnes","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2025081209213887400_bib27","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2025081209213887400_bib28","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1182\/blood.2019000478","article-title":"Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag","volume":"133","author":"Winkler","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2025081209213887400_bib29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.pathol.2016.07.011","article-title":"Eltrombopag: liver toxicity, kidney injury or assay interference?","volume":"48","author":"Choy","year":"2016","journal-title":"Pathology"},{"issue":"10","key":"2025081209213887400_bib30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1515\/cclm-2019-0684","article-title":"Comprehensive characterization and resolution of discrepant spectrophotometric bilirubin results in patients on eltrombopag therapy","volume":"58","author":"Cheng","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"23","key":"2025081209213887400_bib31","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the extend study [published correction appears in Blood. 2018;131(6):709]","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025081209213887400_bib32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2013.098921","article-title":"Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up","volume":"99","author":"Ghanima","year":"2014","journal-title":"Haematologica"},{"issue":"19","key":"2025081209213887400_bib33","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1200\/JCO.2010.29.0387","article-title":"Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis","volume":"28","author":"Teofili","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025081209213887400_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000452992","article-title":"A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol"},{"issue":"7","key":"2025081209213887400_bib35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the extend study","volume":"90","author":"Brynes","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3728\/2403921\/blooda_adv-2024-015102-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3728\/2403921\/blooda_adv-2024-015102-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:21:46Z","timestamp":1755004906000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3728\/537097\/Eltrombopag-in-combination-with-immunosuppressive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":35,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015102","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,24]]}}}